NASDAQ:MNPR

Monopar Therapeutics Stock Insider Trading

etoro logo Buy MNPR
*Your capital is at risk
$76.43
-1.57 (-2.01%)
At Close: Nov 17, 2025

Monopar Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -89.55. In total, the insiders bought 941.14K and sold 1.37M MNPR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-89.55
Buy 941.14K shares
Sell 1.37M shares
66% Buy Activity
Moderate Negative Correlation
Sell Signal High Confidence
Sep 24, 2025

Analysis Breakdown:

  • Strongly supported by a very low Insider Power Score of -89.55.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Sep 30, 2025
Buy
Common Stock
M-Exempt
Cittadine Andrew
Chief Operating Officer
C-Suite Officer 4 327
Value: $353.4K
Sep 30, 2025
Sell
Common Stock
F-InKind
Cittadine Andrew
Chief Operating Officer
C-Suite Officer 1 896
Value: $154.8K
Sep 30, 2025
Buy
Restricted Stock Units
M-Exempt
Cittadine Andrew
Chief Operating Officer
C-Suite Officer 4 327
Value: $353.4K
Sep 30, 2025
Buy
Common Stock
M-Exempt
Robinson Chandler
Chief Executive Officer
CEO / President 8 726
Value: $712.7K
Sep 30, 2025
Sell
Common Stock
F-InKind
Robinson Chandler
Chief Executive Officer
CEO / President 2 646
Value: $216.1K
Sep 30, 2025
Buy
Restricted Stock Units
M-Exempt
Robinson Chandler
Chief Executive Officer
CEO / President 8 726
Value: $712.7K
Sep 30, 2025
Buy
Restricted Stock Units
M-Exempt
Robinson Chandler
Chief Executive Officer
CEO / President 8 726
Value: $712.7K
Sep 30, 2025
Sell
Common Stock
F-InKind
Robinson Chandler
Chief Executive Officer
CEO / President 2 646
Value: $216.1K
Sep 30, 2025
Buy
Common Stock
M-Exempt
Robinson Chandler
Chief Executive Officer
CEO / President 8 726
Value: $712.7K
Sep 30, 2025
Buy
Restricted Stock Units
M-Exempt
Cittadine Andrew
Chief Operating Officer
C-Suite Officer 4 327
Value: $353.4K
Sep 30, 2025
Sell
Common Stock
F-InKind
Cittadine Andrew
Chief Operating Officer
C-Suite Officer 1 896
Value: $154.8K
Sep 30, 2025
Buy
Common Stock
M-Exempt
Cittadine Andrew
Chief Operating Officer
C-Suite Officer 4 327
Value: $353.4K
Sep 24, 2025
Sell
Common Stock
S-Sale
Tactic Pharma Llc
10 Percent Owner
10% Owner 550 229
Value: $35.0M
Sep 24, 2025
Sell
Common Stock
S-Sale
Tactic Pharma Llc
10 Percent Owner
10% Owner 550 229
Value: $35.0M
Jul 14, 2025
Buy
Common Stock
X-InTheMoney
Tsuchimoto Kim R
Director
Director 8 904
Value: $45
Jul 14, 2025
Sell
Common Stock
S-Sale
Tsuchimoto Kim R
Director
Director 8 904
Value: $356.2K
Jul 14, 2025
Sell
Stock Options
X-InTheMoney
Tsuchimoto Kim R
Director
Director 4 704
Value: $24
Jul 14, 2025
Buy
Common Stock
X-InTheMoney
Starr Christopher M
Director
Director 16 800
Value: $84
Jul 14, 2025
Sell
Common Stock
S-Sale
Starr Christopher M
Director
Director 16 800
Value: $672.0K
Jul 14, 2025
Sell
Stock Options
X-InTheMoney
Starr Christopher M
Director
Director 16 800
Value: $84
Jul 14, 2025
Buy
Common Stock
X-InTheMoney
Robinson Chandler
Chief Executive Officer
CEO / President 16 800
Value: $84
Jul 14, 2025
Sell
Common Stock
S-Sale
Robinson Chandler
Chief Executive Officer
CEO / President 16 800
Value: $672.0K
Jul 14, 2025
Sell
Stock Options
X-InTheMoney
Robinson Chandler
Chief Executive Officer
CEO / President 16 800
Value: $84
Jul 14, 2025
Sell
Stock Options
X-InTheMoney
Robinson Chandler
Chief Executive Officer
CEO / President 16 800
Value: $84
Jul 14, 2025
Sell
Common Stock
S-Sale
Robinson Chandler
Chief Executive Officer
CEO / President 16 800
Value: $672.0K

About Insider Power

Insider Power is a proprietary algorithm developed by Stockinvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT MONOPAR THERAPEUTICS INC.
Monopar Therapeutics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubic...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE